Scholar Rock advances SRK-439 for obesity towards 2025 IND; Phase 2 apitegromab trial in 2024 with mid-2025 data

Scholar Rock Holding Corp

Plans to file IND for SRK-439, a novel myostatin inhibitor for obesity, in 2025.
Initiating Phase 2 proof-of-concept trial of apitegromab in combination with GLP-1 RA in obesity in 2024; data expected mid-2025.
Preclinical data show SRK-439 combined with GLP-1 RA reversed lean mass loss and enhanced fat mass loss in diet-induced obese mice.
Pivotal Phase 3 SAPPHIRE trial of apitegromab in SMA fully enrolled; topline data expected Q4 2024.
Leverages selective myostatin inhibition platform; apitegromab already well-tolerated in SMA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.